Since the discovery of leptin, a boom of scienti®c knowledge became available about the OB-protein gene and its role and signi®cance in weight regulation. Both from animal and human research data, serum leptin can probably be considered as one of the best biological markers to re¯ect total body fat, and this ®nding is true over a wide range of body mass indexes (BMIs) and in different pathologies: in normal weight, anorexic and obese subjects; in non insulindependent diabetes mellitus (NIDDM) patients, PCO women, Prader-Willi children and subjects with hypogonadism and growth hormone de®ciency.
Introduction
Obesity is becoming a major health problem in western countries, with an annual growing incidence and its association with increased morbidity and mortality. Furthermore, obesity is a very complex problem in its development, being a multifactorial disease, as well as in its treatment. Knowledge of the mechanisms by which obesity develops can help in prevention and better treatment. The discovery of leptin 1 and the subsequent wealth of research on the subject, has already led to more insight into these mechanisms. 2 Evidence from the research until now points out that leptin is likely to be a crucial hormone in the regulation of body weight, in humans as well as in animal models. 2 It is clear that leptin plays an important role in the regulation of body weight, more speci®cally of body fat stores. Almost all studies hitherto found a strong relationship between leptin and weight, expressed as body mass index (BMI) or percent body fat. 2 ± 4 But for a certain BMI, a large variability in leptin levels is found. 2, 3, 5 Also manifest differences in leptin concentration between men and women have been found by different authors. 6, 7 Given the close interrelationships between body weight, body fat distribution and many hormonal functions, in energy balance regulation, leptin may play an important and triggering role as a hormonal determinant of energy balance in addition to the well-known role played by insulin, catecholamines, glucagon 8 and thyroid hormones. 9 As it is a fact that leptin and its receptor are two important components of a homeostatic system regulating body fat, it is likely that the process of leptin's signalling by the hypothalamus involves the modulation of many other molecules or neurotransmitters such as neuropeptide Y (NPY), melanocytestimulating hormone (MSH), glucagon-like peptide (GLP-1) and corticotropin-releasing factor (CRF).
The involvement of these neuropeptides in food intake behaviour, may potentially lead to the development of new pharmacological therapies in the treatment of overweight and obesity. 10 Whether leptin itself may show some possible therapeutic bene®t, still remains an open question, although initial unpublished ®ndings only suggest a limited success.
Leptin resistance vs low leptin concentrations, in a subset of patients, may probably determine the outcome of clinical trials with leptin injections.
Leptin and obesity
Leptin is synthesized by the fat cells or adipocytes and secreted into the blood stream, so serum leptin concentrations correlate to the amount of body fat. 6, 11 It is signalling the brain about the fat stores of the body and so acts as a part of a feedback mechanism that can function as a`lipostat'. Leptin levels are adapted to changes in energy balance: during fasting 12,13 or weight loss, 3, 14 leptin concentrations decrease; in overfeeding or weight gain, they increase. 15 In human subjects, a highly signi®cant correlation between body fat content and plasma leptin concentrations have been found. Generally, obese humans show high leptin concentrations. 3 Leptin mRNA expression in fat cells also correlates signi®cantly with body fat mass. 3 These data suggest that, in most cases, human obesity is likely to be associated with insensitivity to leptin. Since leptin is secreted normally, even in high amounts, in obese humans, it is hypothesized that the problem in the mechanism of action of leptin in obese people is probably a decreased sensitivity of the brain to the high leptin concentrations. This could be due to a transport problem at the level of the blood-brain barrier, which is described as a saturable binding model. 16, 17 Another cause of leptin-resistance could be a receptor defect. Leptin receptors have been identi®ed 18 and located in the brain, mainly in the hypothalamus, amongst others the arcuate nucleus and the paraventricular nucleus, two sites known to be involved in the regulation of appetite and metabolism. A mutation of the leptin receptor was found in certain animal genetic models of obesity, like the dbadb-mouse 19 and the faafa-rat, and receptor polymorphisms have been described in humans. 20 Also an impaired reaction of other molecules on which leptin acts in the brain, like NPY, may contribute to the impaired sensitivity of leptin in human obese subjects. However, some obese human subjects show lower concentrations of leptin, which may result from an abnormal secretion of leptin from fat stores. This may partially explain the high failure rate of dieting, low leptin concentrations being a potent stimulus for weight gain. 21 Low leptin concentrations have been found to predispose weight gain in preobese Pima Indians. 22 In the majority of obese individuals, at least some leptin is expressed, suggesting that human ob gene mutations are extremely rare. However, two cousins born from an extended family have recently been found to carry a frameshift mutation in the leptin gene and do not have detectable leptin concentrations. 23 Screening for other ob gene mutations in cohorts of obese subjects remained negative until now.
The molecular basis for the apparent linkage of the leptin gene to morbid obesity is not known. Defects in the leptin receptor are not likely to explain the clinical phenotype of the patient, although polymorphisms of the receptor may contribute to explain clinical ®nd-ings in some subsets of patients. Table 1 demonstrates mean leptin concentrations, log leptin concentrations and range in a large cohort of obese subjects (men and women), presenting at our out-patient obesity clinic, and compared to a nonobese control group, indicating that leptin levels are elevated 3±4-fold in obese subjects. In women (n= 118) close and signi®cant correlations exist with BMI (r=0.45; P`0.001), % fat mass (r=0.49; P`0.001).
Leptin and body fat distribution
Apart from the degree of obesity, the pattern of body fat distribution is also important in relation to health risks. Abdominal obesity, and especially visceral fat, is associated with cardiovascular risk factors like hypertension, dyslipidemia and non insulin-dependent diabetes mellitus (NIDDM). 24 The interaction of fat distribution on leptin levels is not yet clear. The ®rst studies regarding this issue found no difference between different types of fat distribution, but recent reports seem to indicate that a difference exists between different fat depots.
Lo Ènnqvist et al 6 found no signi®cant difference in ob expression between subcutaneous and omental fat; however, they only studied the adipose tissue of ®ve subjects. A similar in vitro study by Montague et al, 7 found higher leptin mRNA levels in subcutaneous than in omental adipocytes; the subcutaneousaomental mRNA expression was also much higher in women than in men. This could indicate that leptin plays a role in the control of adipose tissue distribution. The studies published so far, relating leptin to body fat distribution, using anthropometric parameters, came to different conclusions. Haffner et al 5 found similar correlations for leptin with BMI and waist and hip circumferences, and concluded that leptin concentrations are associated with all adipose tissues depots. Weigle et al 25 demonstrated in a group of JapaneseAmericans that subjects with comparable total adipose mass, but different adipose distributions, had comparable circulating leptin concentrations and therefore concluded that leptin is a measure for total body fat BMI=body mass index * P`0.001; ** P`0.05.
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content, independent of regional fat distribution. Lo Ènnqvist et al 26 even found a negative correlation between leptin concentrations and the waist-to-hip ratios (WHR), independent of BMI. They suggested that leptin may protect obese subjects with a gynoid fat distribution from metabolic complications, as it appears to be more associated with peripheral fat depots than with visceral fat. Dua et al 27 found that in women, fasting leptin concentrations correlated with total fat mass, but that the correlation of leptin with visceral fat was dependent on total body fat. They concluded that there must be a different mechanism for the regulation of total body fat and visceral fat. In our own cohort, leptin concentrations were signi®cantly (P`0.001) correlated with most anthropometric parameters such as BMI, hip circumference, fat free mass (FFM), fat mass (FM) in kg and percentage FM. Leptin concentrations were also signi®cantly correlated with total abdominal fat and subcutaneous abdominal fat, but not with visceral fat, waist circumference or WHR.
Most correlations were stronger for men, compared to women, although the male subgroup was smaller. Both in men and women, leptin concentrations were signi®cantly correlated with BMI, waist circumference, hip circumference, FM (in kg) and percentage FM, as determined by bio-impedance, as well as with total abdominal FM, and subcutaneous FM as determined by computed tomography (CT) scan (Figure 1 ). In women, log leptin concentrations were borderline correlated with the WHR and with visceral fat (P=0.05). In men only, there is a signi®cant correlation with visceral FM for leptin concentrations (P=0.014). However, our male subgroup was rather small (n=25), which causes dif®culties in interpretation. The correlation coef®cient in men is higher than in women.
Still, correlations with subcutaneous fat were always signi®cant (P`0.001) and always higher than with visceral fat. After correcting for total body fat, a signi®cant (P=0.05) correlation was found with subcutaneous fat in women only.
In a non-obese control group (n=34), most correlations were higher than for the obese group. Signi®cant correlations were found for BMI, waist and hip circumferences, FM determined by skinfolds and by bioimpedance and total abdominal and subcutaneous fat, but not for the WHR, FFM and visceral fat ( Table 2) .
Although some gender differences still seem to exist in between the leptin-fat distribution, most papers with clinical and in vitro results seem to indicate that leptin is, to a major extent, related to total and subcutaneous fat. In collaboration with the research group in Lille, 28 we recently found a two-fold higher leptin mRNA expression in adipocytes from abdominal subcutaneous adipose tissue biopsies, compared to omental adipose tissue in paired biopsies from 12 subjects. 28 Data from that systematic study, comparing levels of leptin mRNA expression in human visceral vs subcutaneous adipocytes from the same individual, con®rm these observations; this difference was consistently found in lean and in obese subjects. Montague et al 29 suggested that a reduced responsiveness of omental adipocytes to insulin could affect regulation of gene expression and, in this way, play a role in the lower leptin expression in the visceral fat depot. However, the positive effect of insulin on leptin gene expression is relatively weak in humans, compared to the situation in rodents and, more importantly, adipoctyes from obese subjects produce more leptin 30, 31 while they are markedly resistant to the action of insulin. These data suggest that other regulators of leptin gene expression (like, for example, catecholamines and androgens) are more likely to participate in the depot-speci®c difference.
Leptin and diabetes
Since type 2, non-insulin dependent diabetic patients are mostly overweight or obese, higher leptin concentrations can be expected when compared to a control population. Since they are characterized by insulin 
Leptin has been shown to be associated with body composition: high correlations with BMI and body fat were found in the human princeps study 3 and in a series of subsequent studies. 5, 11, 14, 27 These associations seem to be similar in diabetic patients as in nondiabetics. Among our cohort of obese and nonobese non-insulin dependent diabetics, a very strong relationship was found between leptin and BMI, body fat and total abdominal fat, measured by CT scan.
No relationship was found with age in our study. The population described in this study, however, is clearly older than that reported previously, although the hitherto reported relationships with age were not so strong as with other variables.
Also in NIDDM subjects, a clear difference in leptin concentrations was found between men and women: women had signi®cantly higher leptin concentrations than men. This was reported previously and usually explained by the fact that leptin is strongly correlated with the percentage of FM, which is higher in women than in men. Haffner et al 32 found no signi®cant difference in leptin concentrations between diabetics and matched non-diabetics. Also, in a study of Mexican-American diabetics, the diabetic status seemed not to in¯uence leptin concentrations. 32 In our study, no in¯uence of metabolic diabetes control on leptin concentrations was found, neither in its more acute representation (glucose levels), nor by the more chronic re¯ection of it (glycosylated hemoglobin). In our study group, diabetics have lower leptin concentrations than non-diabetics. In the non-obese subjects, mean BMI is slightly higher in the diabetic subjects, but leptin is still signi®cantly lower. When two groups of 32 obese diabetic and non-diabetic women, matched for BMI and percentage FM, were compared, the obese non-diabetic women had signi®cantly higher leptin concentrations than the obese diabetic women (35.9 vs 23.5 ngaml, respectively; P= 0.001). This can be explained by the different fat distribution pattern; after matching for BMI and percentage of body fat, a signi®cant difference in abdominal fat distribution remained. The diabetic women had less subcutaneous FM and signi®cantly (P`0.001) more visceral FM. This adds evidence to the hypothesis that leptin is linked more with subcutaneous fat than visceral fat. The fact that body fat plays a crucial role in leptin behaviour in diabetics, is con®rmed by the recent ®ndings that leptin concentrations are clearly lower in diabetic subjects with lipo-atrophic diabetic complications. 33 A possible effect of insulin on leptin production is still a matter of debate. Although acute effects have been considered unlikely, a prolonged exposure to insulin might in¯uence leptin.
In vitro, insulin stimulates expression of the ob gene and secretion of leptin, in rat as well as in human adipocytes. 34, 35 In animals, insulin injection has been observed to increase ob mRNA in adipose tissue.
In humans, the effect of insulin is not so clear. Relationships between serum leptin concentrations and fasting insulin concentrations were observed, 3, 26 but this association does not persist in subjects with impaired glucose tolerance. 36 In lean insulin-resistant men, basal plasma leptin was found to be higher than in lean insulin-sensitive men with comparable body composition. Insulin sensitivity, as assessed by the minimal model approach, was correlated with plasma leptin concentrations, but not after correction for total body fat. 27 In human experiments, hyperinsulinemia induced by clamp techniques leads to a rise in leptin concentrations, but only in the longer term, 34 not in the short term. 34 In our cohort of type II diabetics, a clear and signi®cant relationship exists between serum insulin and serum leptin (r= 0.56; P`0.001; Figure 2) , with almost comparable correlations with fasting c-peptide and des 31,32 insulin splitt products.
Insulin and leptin concentrations seem to be associated, but plasma insulin does not acutely regulate leptin production. However, a long-term effect of insulin on leptin production was observed both in vivo and in vitro. It is possible that this stimulatory effect of insulin on leptin secretion is due to the trophic effect of insulin on adipocytes.
It was shown very recently by Kieffer et al 37 that leptin receptors are present on insulin secreting A recent new aspect of this interesting ®nding is the mRNA expression of leptin in pancreatic b-cell islets as a direct inhibitory effect of leptin on insulin secretion, as shown by Emillson et al. 38 Within normal concentrations, leptin seems to be able to produce a dose-dependent inhibition of glucose stimulated insulin secretion by isolated islets from obaob mice. At maximum effective concentrations, this inhibitory effect does not exist.
These data suggest that leptin overproduction may modify insulin secretion directly and could be involved in the development of the diabetic syndrome in obese subjects with insulin resistance.
A putative clinical relevance of this leptin-insulin relationship, could be in accordance with the suggestion by Zimmet and colleagues 39, 40 that hyperleptinemia could be the missing link in the metabolic syndrome. The very strong association with insulin concentrations, a key factor in syndrome X, supports this hypothesis.
Leptin and sexual dimorphism
A sexual dimorphism in plasma leptin concentrations was previously described in the literature. 41, 42 It has been repeatedly shown that leptin concentrations are higher in females when compared with males. This difference in leptin concentrations between sexes is frequently explained by pointing at the differences in body composition. This difference was also present in our study group: men had a higher body weight and BMI, but lower % FM. However, the gender difference persisted after leptin concentrations were corrected for %FM or for visceral or subcutaneous FM. Rosenbaum proposed that circulating androgens could have suppressive effect on leptin secretion. 42 In our data, no relationship could be found between testosterone concentrations and leptin. In men, however, signi®cant negative correlations were found with SHBG and oestradiol. This indicates that the gender difference cannot be fully accounted for by the gender difference in body fat. 43 Differences in binding proteins have not been found to explain the difference between the sexes.
In addition, it was demonstrated that men have signi®cantly lower serum concentrations of leptin, compared with premenopausal or postmenopausal women, even when leptin concentrations were corrected for differences in body composition or FM. Both absolute and FM corrected plasma leptin concentrations were unaffected by oestrogen replacement therapy in postmenopausal women. 43 In adolescent boys a similar difference with young girls was also found.
It was shown recently that hypogonadal men with low serum concentrations of testosterone have significantly increase serum concentrations of leptin compared with men without any endocrine disorder. 44 When hypogonadal men are treated effectively with testosterone substitution, serum concentrations of leptin are lowered to the normal range. Therefore, serum testosterone concentrations seem to be a major factor regulating leptin concentrations in men. This suggests that testosterone may regulate mRNA expression in fat cells. This working hypothesis was recently con®rmed in primary human adipocyte culture, showing that both testosterone and its biologically active metabolite dihydrotestosterone are able to reduce leptin secretion by 62% and testosterone was found to suppress leptin mRNA expression to a similar extent. 45 
Leptin endocrinology and puberty
Derived from the differences in gender, interactions between leptin and sex hormones have been suggested. Female obaob mice, usually infertile became fertile again after treatment with recombinant leptin. Administration of leptin to normal young female mice can initiate puberty. This suggests that leptin may be considered as a signalling hormone in the close relationship between body weight, body fat and fertility.
It has been known for more than 20 years that young women should have a certain cut-off weight Figure 2 Relationship of serum leptin with fasting insulin levels in a group of male and female non-insulin treated non insulindependent diabetes mellitus (NIDDM) subjects (r= 0.56; P`0.001).
Leptin: clinical aspects LF Van Gaal et al (fat amount) to attain menarche or to avoid secondary amenorrhea, as seen in girls with anorexia nervosa. 46 Chehab et al 47 were the ®rst to show that obaob, leptin de®cient mice are infertile, but that weight loss induced by leptin administration, may lead to sexual development and restoration of their fertility. Leptin can also advance puberty by several days in normal, female non obese mice, 48 probably by triggering the pulsatile release of GnRH.
In human prepubertal children, pubertal girls increase the percentage of body fat, a mechanism where hormones such as sex and growth hormones are involved. Also leptin concentrations seem to be involved, as was shown by Mantzoros et al 49 ; in young boys a sharp rise in leptin concentrations preceded an increase in circulating concentrations of testosterone and an increase in testicular size. In young girls, accumulation of (subcutaneous) body fat seems to be related in an almost parallel way to increasing levels of leptin, and sex hormones such as estradiol seem to be involved, although this remains a questionable issue.
Growth hormone secretion, also involved in pubertal growth and development, and recently shown to have an important impact on body composition, body fat and distribution, may also be in¯uenced by leptin. 50 The exact effect of growth hormone (GH) on plasma leptin concentrations is not yet known. A recent study of rats by Carro et al 50 suggests that leptin plays a role in the regulation of GH secretion. Administration of leptin antiserum to rats led to a decrease in spontaneous GH secretion; leptin administration to normal fed rats did not modify spontaneous GH secretion.
Patients with GH de®ciency have, in general, a higher body FM, as well as increased subcutaneous fat 51 and increased intraabdominal fat. 51 GH replacement therapy in GH-de®cient patients can lead to a change in body composition, with an increase in lean body mass and a decrease in subcutaneous as well as visceral FM. 51 Even in abdominally obese men without a GH-de®ciency, similar results were found after nine months treatment with GH. 52 Since leptin concentrations are strongly correlated with body composition, especially with FM, it can be expected that changes in plasma leptin concentrations will occur during treatment with GH.
Reports published so far, on GH treatment in adults with GH-de®ciency show contradictory results. Kristensen et al 53 found a decrease in plasma leptin concentrations after four months of treatment, together with the expected increase in lean body mass, decrease in total body fat and BMI, and a signi®cant decrease in visceral as well as subcutaneous fat. When leptin concentrations were corrected for FM, changes in leptin concentrations were no longer signi®cant. They concluded that leptin is not regulated by GH. 53 Florkowski et al 54 also found a signi®cant linear decrease in plasma leptin concentrations over time, during three months of GH treatment, concurrently with a (slight but signi®cant) decrease in total body fat, while no change in BMI occurred. In the study of Bianda et al, 55 GH-de®cient patients were only treated for ®ve days with GH. Here leptin concentrations were increased, as well as plasma concentrations of C-peptide, glucose, NEFA's and IGF-1.
As most papers published so far do not give uniform results, long-term trials will be necessary to give more insight into some endocrine aspects of the leptinagrowth hormone interactions.
Conclusions and perspectives
Leptin is an adipocyte-secreted hormone that seems to play an important role in body weight regulation. Despite a clear bodystat function in animals, its physiological role in humans is not yet fully understood. Personal and literature data have shown that leptin concentrations are high in obese subjects, and correlate with BMI and percentage of body fat. Both in non-diabetic obese subjects and NIDDM patients, leptin concentrations are clearly related to body fat and body fat distribution. Using multiple regression analyses, in men as well as in women, aspects of body composition turned out to be the ®rst predicting variable to explain leptin variability (up to 64% of variance in men). Recent reports seem to indicate that a difference exists in leptin concentration and genetic expression between different fat depots. A recent in vitro study 28 found higher leptin mRNA concentrations in subcutaneous than in omental adipocytes; the subcutaneousaomental mRNA expression was also much higher in women than in men. This could indicate that leptin plays a role in the control of adipose tissue distribution.
Further studies with human GH, known to signi®-cantly reduce visceral fat and to improve insulin sensitivity, will enable us to elucidate the relationship between changes in body fat composition and tentative changes in leptin behaviour.
Other endocrine parameters, like thyroid hormones, seem not to contribute to the concentrations of leptin in both sexes, although the literature reports some con¯icting results in this respect. Age and diabetes metabolic control seem not to explain leptin variability.
A number of neurotransmitters and peptides have been reported to in¯uence food intake and body weight. It seems likely that leptin can activate some of these peptides involved in food intake and energy expenditure. Other hormones or endocrine substances involved in body weight regulation and its distribution, such as catecholamines, corticosteroids, insulin, sex hormones and GH, can also be triggered by leptin, 
